Skip to Content

Active Trials

Title of Study, Principal Investigator

Asthma Studies: CARE has several asthma studies in children 12 months to 18 years of age with asthma looking at the effectiveness of different asthma treatments. Visit the CARE website or study coordinators can be reached at 263-3360.

A Molecular Pathogenesis-Driven Approach for Diagnosis and Treatment of Complement-Based Renal Diseases (KidCOM Study), Sharon Bartosh, MD

Clinical Course of STEC HUS in a Contemporary Group of American Children, Sharon Bartosh, MD

Surveillance for rates of pertussis disease among persons birth through 59 months of age receiving PentacelĂ’ vaccine and among persons vaccinated with other pertussis vaccines, James Conway MD

Infant Nutrition and Risk of Celiac Disease, Istvan Danko, MD

Gene Expression in Isolates of Group A Streptococci Recovered from Patients who are Carriers, Gregory DeMuri, MD

Critical Congenital Heart Disease Screening Program, John Hokanson, MD

Multicenter Prospective Analysis of Pediatric Sedation Practice – The Pediatric Sedation Research Consortium, Greg Holman, MD

Reducing Exit Site Infections and Peritonitis Rates in Pediatric Peritoneal Dialysis Patients, Allison Redpath, MD

A Study of Sweat Testing Using a Quantitative Patch, Michael Rock, MD

The EPIC Observational Study: Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF, Michael Rock, MD

A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy, Michael Rock, MD

Pathogenic Studies in Families with Twins or Siblings Discordant for Systemic Rheumatic Disorders, Judy Smith, MD

Excess IL-23 Production and Underlying Mechanisms in Ankylosing Spondylitis, Judy Smith, MD

Corticosteroids for Children with Febrile Urinary Tract Infections, Ellen Wald, MD

Phase III, partially double-blind study to evaluate consistency and immunogenicity of 3 lots of GSK Biologicals' Hib vaccine 208108 versus ActHIB and Pentacel at 2, 4, 6 and 15-18 months of age in healthy infants, Ellen Wald, MD

Short (5 days) vs. Long (14 days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children, Ellen Wald, MD

Sinusitis in Children and the Nasopharyngeal Microbiome, Ellen Wald, MD

An Interactive Web-based Intervention to Achieve Healthy Weight in Young Children, Ellen Wald, MD

Pediatric Hematology & Oncology Studies

Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies, Ken DeSantes, MD

Intensified Methotrexate, Nelarabine and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia, Ken DeSantes, MD

A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib), Ken DeSantes, MD

A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443 ) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL), Ken DeSantes, MD

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL), Ken DeSantes, MD

Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL), Ken DeSantes, MD

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sarfenib for Patients with High Allelic Ratio FLT3/ITD, Ken DeSantes, MD

COG Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors, Ken DeSantes, MD

Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN), Ken DeSantes, MD

A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens, Ken DeSantes, MD

A Phase III Randomized Trial of Adding Vincristine- topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non- metastatic Ewing Sarcoma, Ken DeSantes, MD

Key Adverse Events after Childhood Cancer, Ken DeSantes, MD

Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma following Myeloablative Therapy and Autologous Stem Cell Rescue, Ken DeSantes, MD

Neuroblastoma Biology Studies, Ken DeSantes, MD

Renal Tumors Classification, Biology, and Banking Study, Ken DeSantes, MD

Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor, Ken DeSantes, MD

Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors: A Phase III Study, Ken DeSantes, MD

Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate Risk Rhabdomyosarcoma (RMS), Ken DeSantes, MD

Reduced Intensity Haploidentical Transplantation with NK Cell Infusion for Pediatric Acute Leukemia and High Risk Solid Tumors, Ken DeSantes, MD

A Group Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens. An Intergroup Rhabdomyosarcoma Study Group Protocol, Ken DeSantes, MD

An open label, expanded access protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma, Ken DeSantes, MD

A Randomized, Phase 2 Study of Single-Agent Erlotinib Versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma, Diane Puccetti, MD

Open-label, Phase 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205, Diane Puccetti, MD

Psychosocial Aspects of Ending Treatment and Long-term Survival of Pediatric Cancer Patients: A Joint Proposal, Diane Puccetti, MD

Last updated: 01/04/2016
webmaster [at] pediatrics [dot] wisc [dot] edu
Copyright © 2016 The Board of Regents of the University of Wisconsin System